Latest

Mar 01, 2018
Jin Zhang outlines four key areas that impacted Chinese pharma in 2017 and looks at how their effects will shape the industry in the years ahead.
Feb 26, 2018
Adhering to new compliance legislation such as Identification of Medicinal Products (IDMP) can bring a pharma company benefits as well as challenges, writes Darren Cooper.
Feb 20, 2018
Scott Beauchamp discussed the future of analytics in the life sciences industry—and look at how peers in other industries have reaped the benefits of being early movers.
Feb 14, 2018
Advocates on all sides applauded the request to increase funding significantly for FDA under the Trump administration’s budget for fiscal year 2019.
Feb 12, 2018
Pharm Exec speaks to Jane Griffiths, Global Head of Actelion, about the current state of the industry's reputation and the work that needs to be done to further build trust with patients and the public.
Feb 08, 2018
Commissioner Scott Gottlieb this week outlined FDA plans to continue the fight against opioid addiction and to prepare a “comprehensive plan” to bolster the market for biosimilars.
Feb 03, 2018
The UK's NICE now has the job of both being a member of the newly named Accelerated Access Collaborative (AAC) and also acting as its Secretariat.
Feb 02, 2018
Pharmaceutical Executive
2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead? Peter Young reports.
Feb 02, 2018
Achieving proper security in industries like life sciences and healthcare, where web-based systems and internal networks are late in coming, may seem a daunting task. But it shouldn't be, writes Dr. Jeff R. Livingstone.
Feb 01, 2018
Payers and pharma must shift away from the traditional one drug–one price approach and expand "indication-based pricing", writes Anaïs Frappé.
native1_300x100
lorem ipsum